Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Cycurion CEO Kevin Kelly issued a shareholder letter outlining the company's strategic shift toward 'predictive intelligence' and offense-informed defense. The company is currently beta testing new predictive capabilities with several organizations and plans to leverage its federal contracts through subsidiaries Axxum and Cloudburst to expand its market presence.
Interim CEO Dean Zikria released a 30-day strategic assessment focusing on advancing the Entolimod clinical pipeline and commercializing the company's Velocity Bioworks CDMO unit. The company is exploring strategic partnerships and licensing deals to bridge the gap between its scientific assets and current market valuation.
Arbutus Biopharma announced that the FDA has lifted the clinical hold on the Investigational New Drug (IND) application for AB-101, its oral PD-L1 inhibitor. The company is now authorized to resume clinical development of the candidate in the United States and is evaluating next steps for its continued development. AB-101 is being developed as a potential treatment for chronic hepatitis B virus (cHBV) infection.
Fractyl Health is implementing a strategic reprioritization to focus on its Revita program, resulting in a 45% workforce reduction and the discontinuation of its Rejuva gene therapy program. The company expects to incur $2 million in severance charges while extending its cash runway into Q2 2027 and reducing quarterly cash burn by approximately 50%.
Biohaven announced that the FDA has accepted its New Drug Application (NDA) resubmission for Vyglxia (troriluzole) for the treatment of spinocerebellar ataxia (SCA). The FDA has assigned a user fee goal date in the first quarter of 2027 and plans to convene an advisory committee meeting to review the application.
Bread Financial Holdings provided a monthly and quarterly performance update for the period ended September 30, 2026, reporting end-of-period credit card and other loans of $18.85 billion. The company disclosed a net principal loss rate of 5.99% for the month and a delinquency rate of 5.57% as of the end of the period.
Blackstone Real Estate Income Trust Business Update
Blackstone Real Estate Income Trust (BREIT) announced preliminary estimated unaudited financial results for the nine months ended September 30, 2026. The company expects same property net operating income (NOI) to have increased by approximately 3% compared to the same period in the prior year.
Cognition Therapeutics has reached alignment with the FDA on the design of its planned Phase 3 registrational study for zervimesine (CT1812) in patients with dementia with Lewy bodies (DLB). The study will focus on mild-to-moderate DLB patients using hallucinations (NPI-2) as a primary endpoint and daily function (ADCS-ADL) as a secondary endpoint.
Medline Inc. initiated a voluntary field action and market exit for all Medline Brand beds, including homecare, bariatric, and long-term care models. The company estimates total costs for the discontinuation and customer credits of up to $220 million, though it does not expect a material impact on its fiscal year 2026 financial guidance.
Arcus Biosciences provided a preliminary estimate of its cash position, reporting approximately $694.0 million in cash, cash equivalents, and marketable securities as of September 30, 2026. This figure is an unaudited estimate released ahead of the company's full quarterly financial results.
Fortress Credit Realty Income Trust Business Update
Fortress Credit Realty Income Trust reported its Net Asset Value (NAV) per share for each of its common share classes as of September 30, 2026. The total NAV for the company was approximately $1.49 billion across 74.7 million outstanding shares, with NAV per share ranging from $19.80 to $20.04 depending on the share class.
Fortress Net Lease REIT reported its Net Asset Value (NAV) per share for each outstanding class of common shares as of September 30, 2026. The company's total NAV was approximately $2.38 billion across 218,160 outstanding shares and units, with Class I shares valued at $10.7535 per share.
Apollo Debt Solutions BDC provided a quarterly shareholder update reporting a net asset value (NAV) per share of $23.78 as of September 30, 2026. The Fund reported a Class I share annualized distribution rate of 9.06% for September and a one-year total net return of 6.05% amid a market environment of elevated interest rates and AI infrastructure investment.
Tron Inc. announced that its Super Representative (SR) node has reached the No. 1 rank on the TRON Network with approximately 3.71 billion delegated TRX tokens. The company intends to operate multiple nodes to expand recurring on-chain revenues and deepen its infrastructure integration within the TRON ecosystem.
Trilogy Metals announced the completion of its 2026 summer field program at the Upper Kobuk Mineral Projects in Alaska, which included 42 drill holes totaling 5,200 meters to support mine design and permitting for the Arctic Project. Additionally, the company's 50/50 joint venture, Ambler Metals, appointed David Thomas as Senior Vice President of Project Development to lead engineering and development efforts.
KKR Private Equity Conglomerate LLC reported its Transactional Net Asset Value (NAV) as of September 30, 2026, totaling approximately $13.27 billion across multiple share classes. The filing provides a breakdown of NAV components, including $10.87 billion in investments at fair value and $2.66 billion in cash and cash equivalents. This update serves as a periodic valuation disclosure for shareholders of the non-traded fund.
KKR Infrastructure Conglomerate LLC reported its Transactional Net Asset Value (NAV) as of September 30, 2026, totaling approximately $8.99 billion. The filing provides a per-share NAV breakdown across multiple share classes, including Class U ($31.15) and Class I-Series 1 ($31.13), used for share sales and repurchases. The update reflects a growth in total Transactional NAV from $8.07 billion as of June 30, 2026.
Silvia, Inc. announced a company-wide cost-cutting initiative expected to deliver over $10 million in annualized savings through reductions in personnel and operating expenses. As part of this restructuring, the Chief Legal Officer, Chief Operating Officer, and Chief Financial Officer have mutually agreed to separate from the company with severance packages including cash and vested shares.
NexMetals Mining Corp. announced a significant update to its Mineral Resource Estimate for the Selebi North deposit in Botswana, nearly tripling Indicated Mineral Resources to 8.95 million tonnes. The update, supported by over 42,000 meters of new drilling, also increased combined Inferred Mineral Resources for the Selebi Mines to 41.95 million tonnes, containing an estimated 2.3 billion pounds of copper equivalent.
Super Micro Computer provided a preliminary business update for Q1 fiscal 2027, significantly raising its revenue and gross margin expectations. The company now expects revenue between $18.5 billion and $19.5 billion, up from previous guidance of $14.5 billion to $15.5 billion, driven by strong demand for AI platforms.
Interparfums reported preliminary net sales of $430 million for the third quarter of 2026, which remained flat compared to the prior year. European-based sales grew 4% driven by Coach and Montblanc fragrances, while U.S.-based sales declined 7% following high growth in the previous quarter.
Annaly Capital Management posted its Third Quarter 2026 financial supplement, providing a snapshot of its investment portfolio and key operational metrics. The company reported a GAAP net loss of $1.36 per share and a book value of $17.86 per share as of September 30, 2026. The filing is classified as a Business/Operational Update because it contains selected financial metrics and a snapshot without a formal GAAP income statement table.
Onex Direct Lending BDC Fund provided a portfolio and business update for the quarter ended September 30, 2026, reporting a Net Asset Value (NAV) per share of $17.04. The company highlighted that its portfolio fair market value was $261.6 million across 43 companies, with 97% of investments in first lien debt and a net leverage ratio of 0.94x.
Anavex Life Sciences announced the completion of clinical conduct for two pharmacology studies (ADME and DDI) for blarcamesine (ANAVEX 2-73) in healthy volunteers. The company also reported FDA clearance of its IND application for Fragile X syndrome and an upcoming November meeting with the FDA regarding its Phase 3 Rett syndrome study.
Capital One Financial Corporation disclosed its monthly credit performance metrics for September 2026, including charge-off and delinquency rates for its Domestic Credit Card and Auto loan portfolios. The Domestic Credit Card segment reported a 3.66% net charge-off rate and a 3.74% 30+ day performing delinquency rate on $260.3 billion in period-end loans.
Lion Copper Corp. announced that its common shares have commenced trading on the Nasdaq Capital Market under the ticker symbol 'LCU' as of October 19, 2026. Additionally, the company has retained Renmark Financial Communications USA Inc. for investor relations services at a fee of $10,000 per month through June 2027.
Oncolytics Biotech announced it will present a trial-in-progress abstract and e-poster for its REO 033 study at the ESMO Congress 2026. The study is a randomized Phase 2 trial evaluating pelareorep in combination with FOLFIRI and bevacizumab for second-line treatment of RAS-mutant, microsatellite-stable metastatic colorectal cancer.
Knightscope reported preliminary Q3 2026 revenue of approximately $8.7 million, representing 177% year-over-year growth. The company also disclosed a corporate record of $27 million in renewals, bookings, and client awards since May 2026. These results are preliminary and do not include a full GAAP income statement or net income figures.
Royal Gold provided preliminary operational metrics for the third quarter of 2026, reporting stream segment sales of $318.3 million and estimated royalty segment sales between $143 million and $149 million. The company also disclosed significant capital allocation activities, including the repayment of $250 million in debt and the repurchase of $49 million of its common stock.
Beeline Holdings implemented an additional cost reduction plan targeting $3 million in annualized savings ($250,000 monthly) through workforce reductions and infrastructure consolidation. The initiative is designed to lower the company's fixed-cost structure and accelerate its path toward positive operating cash flow. The company expects to incur approximately $270,000 in one-time transition expenses through December 1, 2026.